DENVER — Colorado's first-in-the-nation law that allows a state board to limit prescription drug prices is facing a new legal challenge. The pharmaceutical company Amgen is suing the Colorado ...

Getting your Trinity Audio player ready... The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ...

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it. By Rebecca Robbins With a sticker price ...

Add Yahoo as a preferred source to see more of our stories on Google. Sen. Julie Gonzales speaks at the Colorado Capitol on Oct. 7, 2025. Colorado's Prescription Drug Affordability Board voted to set ...

On September 30, the U.S. District Court for the Eastern District of Virginia granted in part and denied in part the Motion to Dismiss filed by Amgen, Inc. and Immunex Corporation (“Amgen”) in a class ...

Colorado finalized the nation’s first prescription drug price cap Oct. 3, establishing an upper payment limit for Enbrel, an autoimmune medication, through the state’s prescription drug affordability ...

Colorado makes history as first state to cap prescription drug prices, targeting Enbrel, used for several autoimmune conditions. Trump pulls US out of more than 30 UN bodies Lack of oil aboard ...

Colorado regulators have approved a dramatic price cap on one of the nation’s best-selling drugs, cutting its price to less than one-third of its previous level, in a novel attempt by a state to ...

DENVER — Colorado became the first state in the country Friday to set a maximum price that insurers and patients can pay for a prescription medication — a move that’s likely to face lawsuits. The ...

Amgen reported 9% revenue growth and 21% non-GAAP EPS growth in the second quarter. Management raised its 2025 revenue guidance by $500 million at the midpoint to $35 billion-$36 billion and increased ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...